Overview
Recombinant Human Thrombopoietin (rhTPO) in Management of Chemotherapy-induced Thrombocytopenia in Acute Myelocytic Leukemia
Status:
Unknown status
Unknown status
Trial end date:
2017-08-01
2017-08-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
Chemotherapy-related myelosuppression usually occurs in AML patients, which induces severe thrombocytopenia and haemorrhage, a leading cause of death. This clinical trial aims at evaluating efficacy and safety of rhTPO in management of chemotherapy-induced thrombocytopenia in acute myelocytic leukemia.Phase:
Phase 3Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Shandong University
Criteria
Inclusion Criteria:- AML patients with PLT count <30×10^9/L during the previous cycle of chemotherapy to
minimize the risk of clinically significant bleeding.
Exclusion Criteria:
- allergic history to biological agents; history of thrombotic or hemorrhagic diseases;
M3 or M7 subtype; pregnancy; hypertension; cardiovascular disease; diabetes; liver and
kidney function impairment;